INmune Bio (NASDAQ: INMB) submits Phase 2 MINDFuL Alzheimer’s trial data

Rhea-AI Filing Summary

INmune Bio Inc. reported that it has submitted a scientific manuscript for peer review describing results from its Phase 2 MINDFuL trial in early Alzheimer’s disease with inflammation. The manuscript, titled “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” was submitted to npj Dementia, a Nature Portfolio journal. The company furnished a press release about this submission as an exhibit to the report.

false 0001711754 0001711754 2025-09-29 2025-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 29, 2025

INMUNE BIO INC.

(Exact name of registrant as specified in charter)

Nevada		001-38793		47-5205835
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of incorporation)				Identification No.)

225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432

(Address of Principal Executive Offices) (Zip Code)

(561) 710-0512 

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per shares		INMB		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 29, 2025, INmune Bio Inc. (the “Company”) issued a press release announcing the submission of a manuscript, titled “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” detailing the results of the Company’s Phase 2 MINDFuL trial for peer review to npj Dementia, a Nature Portfolio journal.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial statements and Exhibits

(d) Exhibits.

99.1		Press Release, dated September 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMUNE BIO INC.
Date: September 30, 2025	By:	/s/ David Moss
		David Moss
		Chief Executive Officer

2

FAQ

What did INmune Bio Inc. (INMB) disclose in this 8-K filing?

INmune Bio Inc. disclosed that it has submitted a manuscript describing results from its Phase 2 MINDFuL trial in early Alzheimer’s disease with inflammation to the journal npj Dementia for peer review, and that it issued a press release about this submission.

What is the title of the Alzheimer’s disease manuscript submitted by INMB?

The manuscript is titled “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial.”

Which journal is reviewing INMB’s Phase 2 MINDFuL trial manuscript?

The manuscript has been submitted to npj Dementia, which is part of the Nature Portfolio of journals, for peer review.

Did INMB include any financial information in this 8-K filing?

No financial results or earnings data are discussed. The filing focuses on the submission of a Phase 2 Alzheimer’s disease trial manuscript and references a related press release as an exhibit.

What exhibit is attached to INMB’s 8-K about the MINDFuL trial?

The filing includes Exhibit 99.1, which is a press release dated September 29, 2025, describing the submission of the Phase 2 MINDFuL trial manuscript, and Exhibit 104, the cover page interactive data file.

Who signed the INMB 8-K related to the Phase 2 MINDFuL trial manuscript?

The report was signed on behalf of INmune Bio Inc. by David Moss, the company’s Chief Executive Officer.